BXRX Share Price | Baudax Bio, Inc. Stock Analysis & Recommendation

Q: How big is Baudax Bio, Inc.?

Market Cap: As of September 2023, Baudax Bio, Inc. has a market capitalization value that is not available. Therefore, it cannot be classified into any market cap type.Recent Quarterly Performance: As of September 2023, the sum of net sales for the latest four quarters is 0.31 million. The sum of consolidated net profit for the same period is -25.83 million.Balance Sheet Snapshot: As of December 2022, the shareholder's funds amount to -24.24 million, and the total assets are 10.03 million.

Q: Is Baudax Bio, Inc. overvalued or undervalued?

As of 12 May 2023, Baudax Bio, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued given its financial metrics and peer comparisons. Notably, Baudax has a P/E ratio of 0.00, an EV to EBIT of -0.65, and an EV to EBITDA of -0.66, all of which indicate significant financial distress.In comparison to its peers, Baudax Bio, Inc. stands out negatively against companies such as ABVC BioPharma, Inc., which has a P/E ratio of -15.31, and Plus Therapeutics, Inc., with a P/E ratio of -0.43. The substantial negative return over the past year of -100% further emphasizes the company's struggles, especially when juxtaposed with the S&P 500's positive return of 10.26% during the same period. Overall, Baudax Bio, Inc. is deemed overvalued based on its current financial standing and performance relative to its peers.

Q: Is Baudax Bio, Inc. technically bullish or bearish?

As of 13 June 2025, the technical trend for Baudax Bio, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the RSI shows a bullish stance on the weekly but is bearish on the monthly, suggesting mixed signals. The daily moving averages are mildly bearish, reinforcing the overall bearish trend. The Bollinger Bands indicate a mildly bearish stance on the weekly and sideways on the monthly. In terms of performance, the company has seen a significant decline over the past three years and five years, with returns of -100%, compared to the S&P 500's gains of 70.41% and 96.61%, respectively. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from the RSI and Bollinger Bands.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Dec 2023)

FII

0.06%

Held by 5 FIIs

DII

99.72%

Held by 0 DIIs

Promoter

0.00%

How big is Baudax Bio, Inc.?

22-Jun-2025

As of September 2023, Baudax Bio, Inc. has an unavailable market capitalization, with net sales of $0.31 million and a consolidated net profit of -$25.83 million over the last four quarters. As of December 2022, shareholder's funds were -$24.24 million, and total assets were $10.03 million.

View full answer

Is Baudax Bio, Inc. overvalued or undervalued?

25-Jun-2025

As of May 12, 2023, Baudax Bio, Inc. is considered overvalued and has moved from a risky valuation grade to "does not qualify," with significant financial distress indicated by a P/E ratio of 0.00 and a negative return of -100% over the past year compared to the S&P 500's positive return of 10.26%.

View full answer

Is Baudax Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of June 13, 2025, Baudax Bio, Inc. shows a mildly bearish trend, with mixed signals from indicators like the MACD and RSI, and a significant decline over the past three to five years compared to the S&P 500.

View full answer

Compare Baudax Bio, Inc. with Similar Stocks

Adial Pharmaceuticals, Inc.Dermata Therapeutics, Inc.180 Life Sciences Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD Million (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.39

Return on Equity

368.47%

Price to Book

0.00

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2023)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

0.0%

1 Year

0.0%

2 Years

-100.0%

3 Years

-100.0%

4 Years

-100.0%

5 Years

-100.0%

Baudax Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

6.98%

EBIT Growth (5y)

12.56%

EBIT to Interest (avg)

-24.41

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.39

Sales to Capital Employed (avg)

0.12

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.75%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

-0.65

EV to EBITDA

-0.66

EV to Capital Employed

3.55

EV to Sales

14.25

PEG Ratio

Dividend Yield

ROCE (Latest)

-547.36%

ROE (Latest)

368.47%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bearish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (0.22%)

Foreign Institutions

Held by 5 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is 73.97% vs 1.35% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.30",
          "val2": "-4.00",
          "chgp": "-32.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.30",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.80",
          "val2": "-3.00",
          "chgp": "226.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.90",
          "val2": "-7.30",
          "chgp": "73.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 18.18% vs 120.00% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -196.97% vs 73.98% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "1.10",
          "chgp": "18.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-33.60",
          "val2": "-49.60",
          "chgp": "32.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "2.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-21.10",
          "val2": "33.40",
          "chgp": "-163.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-58.80",
          "val2": "-19.80",
          "chgp": "-196.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-28,166.30%",
          "val2": "-48,496.30%",
          "chgp": "2,033.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ

Sep'23

Jun'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.30

-4.00

-32.50%

Interest

0.10

0.30

-66.67%

Exceptional Items

3.80

-3.00

226.67%

Consolidate Net Profit

-1.90

-7.30

73.97%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Jun 2023

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2023 is 73.97% vs 1.35% in Jun 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

1.30

1.10

18.18%

Operating Profit (PBDIT) excl Other Income

-33.60

-49.60

32.26%

Interest

0.00

2.30

-100.00%

Exceptional Items

-21.10

33.40

-163.17%

Consolidate Net Profit

-58.80

-19.80

-196.97%

Operating Profit Margin (Excl OI)

-28,166.30%

-48,496.30%

2,033.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2022 is 18.18% vs 120.00% in Dec 2021

Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -196.97% vs 73.98% in Dec 2021

All Annual Results

Company CV

About Baudax Bio, Inc.

Baudax Bio, Inc.

Pharmaceuticals & Biotechnology

Baudax Bio, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The Company’s lead product candidate is IV injectable form of Meloxicam, a long-acting preferential cyclooxygenase (COX)-2 inhibitor. The Company’s product pipeline also includes other early-stage product candidates, including two neuromuscular blocker agents (NMBAs) and a related chemical reversal agent, and Dexmedetomidine (Dex)- intranasal (IN), an intranasal formulation of dexmedetomidine. The Company is developing an intermediate-acting NMBA, RP100; an ultrashort-acting NMBA, RP2000, and a reversal agent specific to its NMBAs.

Company Coordinates

Company Details

490 Lapp Rd , MALVERN PA : 19355-1212

Tel:

https://www.baudaxbio.com/

Registrar Details